All In Biotech

Free tool

FAERS Monitor: Spevigo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761244 or its brand name (Spevigo, Spesolimab-Sbzo). Reports on generic versions are filed under their own applications.

Reports

403

Serious

213

53% of reports

Hospitalization

88

Death reported

28

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • generalised pustular psoriasis82
  • drug ineffective54
  • off label use26
  • pruritus22
  • rash20
  • fatigue19
  • pustular psoriasis19
  • psoriasis16
  • pustule15
  • maternal exposure during pregnancy14
  • asthenia13
  • pyrexia13
  • diarrhoea12
  • therapeutic product effect incomplete12
  • urinary tract infection12

Reports by year received

View as table
YearReports
202213
202364
202498
2025115
2026113

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,756 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
generalised pustular psoriasisSignal8220595.616263.01,196,479
pustuleSignal15332.5202.04,602
pustular psoriasisSignal19290.3186.95,165
therapeutic product effect incompleteSignal128.85.076
maternal exposure during pregnancySignal148.24.982
psoriasisSignal166.44.068
urinary tract infectionSignal123.72.121
pruritusSignal223.02.028
rashSignal202.41.615
drug ineffectiveSignal542.11.734
pyrexia132.01.15
asthenia131.81.14
off label use261.51.15
fatigue191.30.81
diarrhoea121.00.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.